Tourette Syndrome – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Tourette Syndrome – Pipeline Review, H2 2018’, provides an overview of the Tourette Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tourette Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome

– The report reviews pipeline therapeutics for Tourette Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Tourette Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Tourette Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Tourette Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abide Therapeutics Inc

Catalyst Pharmaceuticals Inc

Neurocrine Biosciences Inc

Psyadon Pharmaceuticals Inc

SOM Biotech SL

Teva Pharmaceutical Industries Ltd

Therapix Biosciences Ltd

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tourette Syndrome Overview

Tourette Syndrome Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tourette Syndrome Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tourette Syndrome Companies Involved in Therapeutics Development

Abide Therapeutics Inc

Catalyst Pharmaceuticals Inc

Neurocrine Biosciences Inc

Psyadon Pharmaceuticals Inc

SOM Biotech SL

Teva Pharmaceutical Industries Ltd

Therapix Biosciences Ltd

Zynerba Pharmaceuticals Inc

Tourette Syndrome Drug Profiles

(amfetamine + guanfacine hydrochloride) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-1431 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bevantolol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPP-115 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

deutetrabenazine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ecopipam hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THX-110 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THX-120 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valbenazine tosylate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vigabatrin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYN-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tourette Syndrome Dormant Projects

Tourette Syndrome Discontinued Products

Tourette Syndrome Product Development Milestones

Featured News & Press Releases

Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome

Apr 10, 2018: Abide Therapeutics Presents Positive Data from a Phase 1b Study of ABX-1431 in Tourette Syndrome at the American Academy of Neurology 70th Annual Meeting

Apr 09, 2018: Therapix Biosciences Announces Top line Results of Phase IIa Study at Yale University for Tourette Syndrome Program

Feb 28, 2018: Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO® (deutetrabenazine) for the Treatment of Tourette syndrome in Pediatric Patients

Feb 07, 2018: Abide Therapeutics to Participate in February 2018 Investor Conferences

Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

Jan 03, 2018: Zynerba Pharmaceuticals Provides Update on fibromyalgia Drug Candidate ZYN-001

Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program

Nov 28, 2017: Abide Therapeutics Reports Positive Top line Data from Phase 1b Study of ABX-1431 in Tourette Syndrome

Oct 25, 2017: Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA in Children and Adolescents with Tourette Syndrome

Oct 23, 2017: Neurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette Syndrome

Oct 11, 2017: Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)

May 23, 2017: Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA For Treatment of Tourette Syndrome

May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome

Apr 18, 2017: Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Tourette Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Tourette Syndrome Pipeline by Abide Therapeutics Inc, H2 2018

Tourette Syndrome Pipeline by Catalyst Pharmaceuticals Inc, H2 2018

Tourette Syndrome Pipeline by Neurocrine Biosciences Inc, H2 2018

Tourette Syndrome Pipeline by Psyadon Pharmaceuticals Inc, H2 2018

Tourette Syndrome Pipeline by SOM Biotech SL, H2 2018

Tourette Syndrome Pipeline by Teva Pharmaceutical Industries Ltd, H2 2018

Tourette Syndrome Pipeline by Therapix Biosciences Ltd, H2 2018

Tourette Syndrome Pipeline by Zynerba Pharmaceuticals Inc, H2 2018

Tourette Syndrome Dormant Projects, H2 2018

Tourette Syndrome Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Tourette Syndrome, H2 2018 8

Number of Products under Development by Companies, H2 2018 9

Number of Products by Top 10 Targets, H2 2018 13

Number of Products by Stage and Top 10 Targets, H2 2018 13

Number of Products by Top 10 Mechanism of Actions, H2 2018 15

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 15

Number of Products by Routes of Administration, H2 2018 17

Number of Products by Stage and Routes of Administration, H2 2018 17

Number of Products by Stage and Top 10 Molecule Types, H2 2018 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports